Bristol Myers offers a big premium to reel in MyoKardia's cardio pipeline with a $13B buyout
Five months after MyoKardia $MYOK swept its late-stage pivotal on its lead heart drug — highlighting its success with a precision med approach to cardiology — Bristol Myers Squibb is stepping up with a $13.1 billion buyout tied to a big premium.
Bristol Myers is paying $225 a share — a 61% premium — to get its hands on the cardio player, highlighting its interest in mavacamten, where execs see a first-in-class role treating obstructive hypertrophic cardiomyopathy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.